These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 2659869)

  • 21. [Combination chemotherapy of advanced urothelial cancer with methotrexate, vinblastine, adriamycin and cisplatin (M-VAC)].
    Nakagawa S; Nakao M; Toyoda K; Nukui M; Takada H; Ebisui K; Watanabe H; Kobayashi T; Maegawa M
    Nihon Hinyokika Gakkai Zasshi; 1988 Sep; 79(9):1510-5. PubMed ID: 3244217
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group.
    Kuroda M; Kotake T; Akaza H; Hinotsu S; Kakizoe T
    Jpn J Clin Oncol; 1998 Aug; 28(8):497-501. PubMed ID: 9769784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
    Sella A; Flex D; Gafni D; Rabinovitz O; Sulkes A; Baniel J
    Harefuah; 1999 Feb; 136(4):268-71, 340, 339. PubMed ID: 10914214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Ahmed T; Weiselberg LR; Geller N; Hollander PS; Herr HW; Sogani PC
    J Urol; 1985 Mar; 133(3):403-7. PubMed ID: 4038749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium.
    Yamada Y; Itoh Y; Aoki S; Nakamura K; Taki T; Naruse K; Tobiume M; Zennami K; Katsuda R; Kato Y; Watanabe M; Nishikawa G; Minami M; Nakahira M; Ukai S; Sawada M; Kitamura A; Honda N
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1079-83. PubMed ID: 19277660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Schedule-intensified M-VAC chemotherapy for advanced urothelial cancer with recombinant human granulocyte colony stimulating factor (rhG-CSF).
    Noguchi S; Kubota Y; Shuin T; Hosaka M; Miura T; Kondoh I
    Int J Urol; 1994 Jun; 1(2):140-2. PubMed ID: 7543010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical evaluation of M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy for advanced urothelial cancer].
    Mikami K; Nakagawa S; Takada H; Ebisui K; Sugimoto K; Watanabe H; Maegawa M; Nakao M
    Hinyokika Kiyo; 1994 Apr; 40(4):303-7. PubMed ID: 8191968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical studies of chemotherapy for patients with a solitary kidney after nephroureterectomy for advanced upper urothelial transitional cell carcinoma].
    Tsujimura A; Takayama H; Tsukikawa M; Imazu T; Sugao H; Takaha M
    Hinyokika Kiyo; 1995 Mar; 41(3):183-9. PubMed ID: 7741070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors affecting the outcome of patients with advanced urothelial cancer following chemotherapy with methotrexate, vinblastine, adriamycin, and cisplatin.
    Igawa M; Ohkuchi T; Ueda M; Usui T
    Cancer Chemother Pharmacol; 1992; 30 Suppl():S77-80. PubMed ID: 1394824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience.
    Boutan-Laroze A; Mahjoubi M; Droz JP; Charrot P; Fargeot P; Kerbrat P; Caty A; Voisin PM; Spielmann M; Rey A
    Eur J Cancer; 1991; 27(12):1690-4. PubMed ID: 1782084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium.
    Miller RS; Freiha FS; Reese JH; Ozen H; Torti FM
    J Urol; 1993 Jul; 150(1):65-9. PubMed ID: 8510277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced urothelial cancer.
    Ueki O; Hisazumi H; Uchibayashi T; Naito K; Tajiri S; Takemae K; Kawaguchi K; Kameda K; Nishino A; Nango C
    Cancer Chemother Pharmacol; 1992; 30 Suppl():S72-6. PubMed ID: 1394823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma.
    Bellmunt J; Ribas A; Eres N; Albanell J; Almanza C; Bermejo B; Solé LA; Baselga J
    Cancer; 1997 Nov; 80(10):1966-72. PubMed ID: 9366300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Combination chemotherapy of M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) for advanced uroepithelial cancer].
    Hatachi K; Shigeta M; Kokehara O; Matsuki S; Fukushima M; Kadena H
    Nihon Hinyokika Gakkai Zasshi; 1990 Mar; 81(3):433-8. PubMed ID: 2359221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors.
    Sternberg CN; de Mulder PH; van Oosterom AT; Fossa SD; Giannarelli D; Soedirman JR
    Ann Oncol; 1993 May; 4(5):403-7. PubMed ID: 8353075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perioperative methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) for poor risk transitional cell carcinoma of the bladder: an Eastern Cooperative Oncology Group pilot study.
    Dreicer R; Messing EM; Loehrer PJ; Trump DL
    J Urol; 1990 Nov; 144(5):1123-6; discussion 1126-7. PubMed ID: 2231884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cisplatin-based chemotherapy for the treatment of advanced transitional-cell carcinoma of the urinary tract--a preliminary report.
    Lee MH; Chen MT; Chen KK; Lin AT; Lee YH; Lee LM; Chang YM; Chang LS; Liu JM; Hsieh RK
    Cancer Chemother Pharmacol; 1992; 30 Suppl():S81-4. PubMed ID: 1394825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
    Dreicer R; Manola J; Roth BJ; See WA; Kuross S; Edelman MJ; Hudes GR; Wilding G
    Cancer; 2004 Apr; 100(8):1639-45. PubMed ID: 15073851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ; Elson P; Dreicer R; Hahn R; Nichols CR; Williams R; Einhorn LH
    J Clin Oncol; 1994 Mar; 12(3):483-8. PubMed ID: 7509853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.